Serina Therapeutics (SER) Chief Scientific Officer reports 13,000-share sale

Rhea-AI Filing Summary

Serina Therapeutics Chief Scientific Officer reports option exercise and sale of shares. On 01/08/2026, Randall Moreadith exercised stock options for 13,000 shares of Serina Therapeutics, Inc. common stock at an exercise price of $0.06 per share. On the same date, he sold 13,000 shares of common stock at a weighted average price of $2.6887 per share, with individual sale prices ranging from $2.85 to $2.60. Following these transactions, he reported owning no shares of common stock directly and 339,186 stock options, which the filing states are fully vested.

Insider Trade Summary

Net Seller: 13,000 shares ($34,953)

Net Sell 3 txns

Insider Moreadith Randall

Role Chief Scientific Officer

Sold 13,000 shs ($35K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	13,000	$0.00	--
Exercise	Common Stock	13,000	$0.06	$780.00
Sale	Common Stock	13,000	$2.6887	$35K

Holdings After Transaction: Stock Option (right to buy) — 339,186 shares (Direct); Common Stock — 13,000 shares (Direct)

Footnotes (1)

1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.60. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The stock options are fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moreadith Randall

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE AL 35806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		M		13,000	A	$0.06	13,000	D
Common Stock	01/08/2026		S		13,000	D	$2.6887(1)	0(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.06	01/08/2026		M			13,000	(2)	05/06/2031	Common Stock	13,000	$0	339,186	D

Explanation of Responses:

1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.60. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

2. The stock options are fully vested.

Remarks:

	/s/ Randall Moreadith	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Serina Therapeutics (SER) disclose in this filing?

The filing shows that Chief Scientific Officer Randall Moreadith exercised 13,000 stock options for common stock and sold 13,000 shares of Serina Therapeutics, Inc. common stock on 01/08/2026.

At what prices did the Serina Therapeutics (SER) insider exercise and sell shares?

Randall Moreadith exercised stock options at an exercise price of $0.06 per share and sold the resulting 13,000 shares at a weighted average price of $2.6887 per share, with actual sale prices ranging from $2.85 to $2.60.

How many Serina Therapeutics (SER) shares and options does the insider own after this transaction?

After the reported transactions, Randall Moreadith reported owning 0 shares of Serina Therapeutics, Inc. common stock directly and 339,186 stock options, which the filing notes are fully vested.

What role does the reporting person hold at Serina Therapeutics (SER)?

The reporting person, Randall Moreadith, is identified as an officer of Serina Therapeutics, Inc., serving as Chief Scientific Officer.

Were the Serina Therapeutics (SER) stock options involved in this filing vested?

Yes. A footnote in the filing states that the stock options are fully vested, indicating that all 339,186 reported options, including the 13,000 exercised, were fully vested at the time of the transaction.

What is the significance of the weighted average sale price in the Serina Therapeutics (SER) insider trade?

The filing explains that the reported sale price of $2.6887 per share is a weighted average for multiple trades executed between $2.85 and $2.60, and that detailed trade breakdowns are available upon request.